Breaking Finance News

Genedrive Plc (LON:GDR) target price held steady at 200.00GBX, issued a report today by Peel Hunt

Genedrive Plc (LON:GDR) had its target price hold steady to 200.00GBX by Peel Hunt in a report released 10/11/2016. The new target price indicates a possible upside of 2.2% based on the company's last closing price.

Previously on Wednesday September 21, 2016, Peel Hunt reported on Genedrive Plc (LON:GDR) held steady the target price at 200.00GBX. At the time, this indicated a possible upside of 2.33%.

Yesterday Genedrive Plc (LON:GDR) traded -4.00% lower at 62.50GBX. The company’s 50-day moving average is 68.75GBX and its 200-day moving average is 83.22GBX. The last closing price is down -27.90% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,500 shares of the stock were exchanged, down from an average trading volume of 4,899

See Chart Below

Genedrive Plc (LON:GDR)

Genedrive Plc has a 52 week low of 50.00GBX and a 52 week high of 180.13GBX The company’s market cap is currently 0 GBX.

General Information About Genedrive Plc (LON:GDR)

Genedrive plc, formerly Epistem Holdings plc, is a United Kingdom-based molecular diagnostics company. The Company is engaged in developing a point of need or point of care diagnostics platform for the diagnosis of infectious diseases, and for use in patient stratification (genotyping), pathogen detection and other indications. It has two segments: Preclinical Research Services and Personalised medicine. It offers Genedrive platform and tuberculosis or rifampicin resistance (MTB/RIF) test in India. The Genedrive molecular diagnostic system is a genotyping and sequence analysis device. The Preclinical Research Services division delivers preclinical services, testing efficacy and specificity of client drugs. The Personalised Medicine division focuses on advances in molecular technology to identify and develop diagnostic tests and biomarkers for use on its Genedrive diagnostic platform or in collaboration with drug development partners. The Company focuses on Novel Therapies division.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *